08:02 AM EDT, 09/01/2026 (MT Newswires) -- BofA Global Research on Tuesday noted Novartis' (NOVN.SW) report that its phase 3 trials for remibrutinib met their primary endpoint of "significantly" reducing annualized relapse rate in adult patients with relapsing multiple sclerosis, compared with teriflunomide, with no liver safety issues. "We forecast $3bn un-risk adjusted peak sales for remi, with upside potential based on exact progression data[.] The positive remi MS data likely increases investor conviction in remi's potential as a [more than] $10bn asset across indications," the research firm said. "We model a total $26bn MS market and see potential for [Bruton's tyrosine kinase inhibitors] to replace most existing orals (c$7bn) due to better efficacy, and potential to compete in certain settings vs CD20s (c$15bn)." The buy rating on the stock was reiterated, with a price objective of 140 francs. Analysts also highlighted five data readouts as key catalysts in the second half, including the detailed phase 3 data for remibrutinib in multiple sclerosis set to be presented at MSToronto2026 meeting in October, as well as the late-stage data for remibrutinib in hidradenitis suppurativa and pelacarsen on secondary cardiovascular event prevention.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.